Company Vision
Anaconda Medical is dedicated to improving treatment outcomes for patients with the most challenging cerebral aneurysms and vascular malformations
The unmet need
A cerebral aneurysm is a weakened area in a brain artery that bulges and fills with blood, potentially leading to pressure on brain tissue or rupture which can lead to death. According to (BAF) Brain Aneurysm Foundation about 6.8 million people in the U.S. have unruptured brain aneurysms, and ruptures cause nearly 500,000 deaths annually worldwide, with 50% of victims being under 50. When ruptured, about 50% of cases are fatal, and 66% of survivors suffer permanent neurological damage. Traditional treatments include surgical clipping, which carries high risks and longer recovery, while minimally invasive methods like transcatheter treatments (embolization coils, intrasaccular devices, and flow diverters) are preferred. However, these devices struggle to treat large and giant aneurysms in a single deployment, leading to longer procedures, increased cost, and complications. Anaconda Medical aims to develop a new, innovative device for treating large and giant aneurysms with a single device via a small microcatheter, improving treatment efficiency, reducing complications, and lowering costs. Current devices like linear coils, flow diverters, and intra-aneurysmal flow diverters have limitations in size, procedure time, and risks, particularly for larger aneurysms. The proposed device would treat aneurysms over 10 mm with a single device and smaller microcatheters, addressing these limitations and reducing procedure time and complications.
The Technology
The technology enables constructing of a superstructure nitinol mesh that expands in three dimensions in the vascular system to occlude blood flow. One application of the technology is intrasaccular device for cerebral aneurysms. The device deploys in the aneurysm sac with higher volume fill packing, allowing occlusion of large and giant aneurysms in a single unit, with good clinical efficiency and significantly shorter treatment time compared to existing solutions like coils. The technology enables delivery to the aneurysm by a smaller microcatheters than the existing devices, enabling safe and efficient insertion into the small blood vessels of the brain. The technology versatility allows other applications for vessel occlusions such as Dural Arteriovenous Fistula, AVM etc.
The technology is protected by multiple granted patents worldwide.
The Market
The global cerebral aneurysm market size was valued at 1.6$ Billon in 2024 and is projected to exhibit an annual growth rate of approximately 8% in the next five years. This steady growth will be supported by factors such as the aging global population, lifestyle changes, increased awareness, and advancements in medical technology. Additionally, the development of more effective and minimally invasive treatment options will further boost market demand. The primary markets for this device are developed regions such as the United States, Europe, and the Asia, with a strong focus on the US market, where reimbursement for these procedures is well-established. The Asian market, in particular, is expected to show high demand due to the significantly higher incidence of brain diseases in the region—approximately 2.5 times higher than the global average. Currently, endovascular treatments for large and giant aneurysms primarily involve coils and flow diverters. However, these treatments have limitations, particularly in terms of effectiveness for larger aneurysms.
The versatility of the new technology offers additional applications for vessel occlusions, expanding its market potential beyond just aneurysm treatment and positioning the device to address a broader range of vascular conditions. This innovation is expected to capture a significant share of the market, offering improved clinical outcomes and reduce procedure time and risk.
The Team
Dr. John DeMeritt, MD
Dr. John DeMeritt is an Interventional radiologist /neuroradiologist and device inventor with 30 years of clinical experience. Dr. DeMeritt is fellowship trained in interventional radiology (Yale University), neuroradiology (Yale University), and interventional neuroradiology (Columbia University). Dr. DeMeritt currently is on staff at the Hackensack University Medical Center where he also does research in Radiology. He has multiple medical publications and granted US patents; numerous presentations at the Global Embolization Symposium & Technologies (GEST Meeting) in the past 5 years; and at the Society of Interventional Radiology (SIR Meeting) in 2022.
Aaron Feldman
Mr. Aaron Feldman is an accomplished entrepreneur with more than 20 years’ experience in the R&D and commercialization of medical devices. Former CEO of Rafael Medical Technologies, CardioFlow and co-founder in several advanced-staged start-up companies in a wide range of medical domains including Ark Surgical (GYN Surgery), Restore Medical (Cardiovascular Implant) and FetalEase (Obstetrics).
Shady Jahshan, MD
Dr. Shadi Jhashan is a specialist in neurosurgery with more than 20 years of clinical experience. He did neuroendovascular surgery fellowship at the Department of Neurosurgery, Gates Vascular Institute, State University at Buffalo New York, USA. Dr. Jhashan is the head of the Interventional Neuroradiology Unit in the Neurosurgery Department at the Galil Medical Center. Dr. Jhashan founded and managed the Stroke Catheterization Unit at Ichilov Hospital. He consultant to several companies in the field of neurointerventional devices.
Reuven Filman
Mr. Reuven Filman is an accomplished technology executive with over 20 years of leadership experience in the medical device, telecommunications, and consumer electronics industries. Possesses extensive experience leading high-performing teams to deliver complex, multidisciplinary projects with a strong focus on innovation and strategic growth. A key player in several start-ups and corporations across the drug delivery, cardiovascular, and neurology sectors. A skilled mechanical engineer with a proven track record of driving engineering design from concept to commercialization. Holds a B.Sc. in Mechanical Engineering from the Technion.
Contact Us
Reuven Filman CEO
0546217511